Robert Calnon in Friday’s 28 September Eureka Report commented most favourably on ACR (and SRX). An extract from the report. “Another stock that I consider has recently crossed the threshold from biotech hopeful toward industrial stock status is Acrux (ACR:ASX). Like SRX, ACR has a market capitalisation of around $500 million and is right in my investment universe sweet spot of mid cap industrial stocks.”
"Consensus estimates have the company making $0.06 cents per share in FY13, moving to $0.25cps in FY14. At current levels the stock is trading on around 13.3x FY14 earnings, which may sound a little expensive but the growth rate more than justifies the price. After quadrupling earnings in FY14, ACR is estimated by analysts to go on and double its earnings in FY15."
Read more at EurekaReport: http://www.eurekareport.com.au/article/2012/9/28/small-caps/swallowing-biotechs-small-doses#ixzz280KWTkCX
ACR Price at posting:
$3.21 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)